TargetMol

Cilomilast

Product Code:
 
TAR-T6445
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6445-1mg1mg£97.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6445-2mg2mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6445-5mg5mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6445-1mL1 mL * 10 mM (in DMSO)£141.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6445-10mg10mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6445-25mg25mg£286.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6445-50mg50mg£454.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6445-100mg100mg£631.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Cilomilast is a potent PDE4 inhibitor with IC50 of about 110 nM, has anti-inflammatory activity and low central nervous system activity. Phase 3.
CAS:
153259-65-5
Formula:
C20H25NO4
Molecular Weight:
343.423
Pathway:
Metabolism
Purity:
0.98
SMILES:
COc1ccc(cc1OC1CCCC1)[C@]1(CC[C@@H](CC1)C(O)=O)C#N
Target:
PDE

References

Kobayashi M, et al. Int Immunopharmacol. 2011, 11(6), 732-739. Sadrai Z, et al. Invest Ophthalmol Vis Sci. 2012. Pace E, et al. Cell Immunol. 2011, 268(1), 47-53. Barnette MS, et al. J Pharmacol Exp Ther. 1998, 284(1), 420-426. Griswold DE,et al. J Pharmacol Exp Ther. 1998, 287(2),705-711.